-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In recent years, the domestic pharmaceutical industry is setting off a wave of financing
.
In the first half of 2021 alone, the number of IPO pharmaceutical companies on the Science and Technology Innovation Board has reached 23, with a total financing amount exceeding 18 billion yuan
.
In 2022, this wave of financing will continue.
Recently, many pharmaceutical companies have announced the completion of financing, which will be used for the research and development and promotion of new drugs
.
For example, a few days ago, Zhejiang Shimai Pharmaceutical announced the completion of a new round of financing of hundreds of millions of yuan.
This round of financing was led by Taikun Fund, a subsidiary of Tigermed.
Guangdong Yuemin Investment, Hongxin Capital, Anji Maisheng, Zhejiang Yongxi, Hangzhou Cheng and co-investment, Binjiang District Government Fund Hang Gao Investment also participated in the investment, and old shareholders such as Betta Pharmaceuticals and Cybernaut continued to support
.
Haoyue Capital acted as the exclusive financial advisor for this round of financing
.
It is understood that the funds raised in this round will be mainly used to promote the development of core blockbuster products such as class I new drug DNV3 (solid tumors and lymphomas), dual-antibody new drug SMET12 (solid tumors with high EGFR expression), and CMD003 (autoimmune system diseases).
Clinical trials at home and abroad, to promote the clinical application of CMD009 (solid tumor), CMD011 (liver cancer), CMDE002 (solid tumor), etc.
and the development of other follow-up pipeline projects, accelerate the launch of drugs, and promote the industrialization of a series of innovative antibody products
.
Prior to this, Purui Benchmark Technology (Beijing) Co.
, Ltd.
(hereinafter referred to as "Prui Benchmark") has actually completed tens of millions of yuan in B+ round financing, which was invested by Suzhou High-tech Venture Capital Group (hereinafter referred to as "Su Gaoxin Venture Capital").
”)
.
It is reported that this B+ round of financing will help the company to accelerate the upgrade of the AIBERT® (Oncology Multi-omics Data Mining System for New Drug Development) platform, including the computing module (bioinformatics platform) and the experimental module (multi-omics functional laboratory) ) construction
.
In addition, Nanjing Yuxi Pharmaceutical Technology Co.
, Ltd.
(hereinafter referred to as "Yuxi Medicine") also announced some time ago that it has completed the pre-A round of tens of millions of RMB financing
.
This round of financing was led by Materia Medica, followed by Jiuyou Capital, Chang Development, Aibo Qingshi and Mingfeng Capital
.
This round of financing will be mainly used for product clinical trials, pipeline research and development, innovative technology platform construction and team supplementation
.
In addition, Yuguo Bio also announced that it has completed a C round of financing of 300 million yuan, which was exclusively led by Shanghai Biomedical Fund, and the old shareholder LYFE Zhouling Capital joined the investment
.
According to the announcement, the raised funds will continue to be invested in the research and development of new products and the in-hospital localized deployment of pathogenic NGS
.
According to incomplete statistics, in January 2022, more than 20 pharmaceutical companies have completed investment in the field of new drugs, and the total financing amount has exceeded 5 billion yuan.
Among them, it is worth mentioning that industry analysts believe that from this year's financing of pharmaceutical companies.
In general, the focus of pharmaceutical companies is no longer the same as before, focusing on popular fields such as "tumor, car-t, double antibody", but gradually began to choose more unpopular and more subdivided field layouts
.
This means that segmentation and specialization may gradually become the only way for future innovative pharmaceutical companies
.
In this context, innovative pharmaceutical companies, focusing on subdivision fields, choose to become small and dedicated companies with characteristics, and in the future, it will be easier to obtain real core competitiveness.
It is recommended by the industry that related companies can deploy as soon as possible
.
.
In the first half of 2021 alone, the number of IPO pharmaceutical companies on the Science and Technology Innovation Board has reached 23, with a total financing amount exceeding 18 billion yuan
.
In 2022, this wave of financing will continue.
Recently, many pharmaceutical companies have announced the completion of financing, which will be used for the research and development and promotion of new drugs
.
For example, a few days ago, Zhejiang Shimai Pharmaceutical announced the completion of a new round of financing of hundreds of millions of yuan.
This round of financing was led by Taikun Fund, a subsidiary of Tigermed.
Guangdong Yuemin Investment, Hongxin Capital, Anji Maisheng, Zhejiang Yongxi, Hangzhou Cheng and co-investment, Binjiang District Government Fund Hang Gao Investment also participated in the investment, and old shareholders such as Betta Pharmaceuticals and Cybernaut continued to support
.
Haoyue Capital acted as the exclusive financial advisor for this round of financing
.
It is understood that the funds raised in this round will be mainly used to promote the development of core blockbuster products such as class I new drug DNV3 (solid tumors and lymphomas), dual-antibody new drug SMET12 (solid tumors with high EGFR expression), and CMD003 (autoimmune system diseases).
Clinical trials at home and abroad, to promote the clinical application of CMD009 (solid tumor), CMD011 (liver cancer), CMDE002 (solid tumor), etc.
and the development of other follow-up pipeline projects, accelerate the launch of drugs, and promote the industrialization of a series of innovative antibody products
.
Prior to this, Purui Benchmark Technology (Beijing) Co.
, Ltd.
(hereinafter referred to as "Prui Benchmark") has actually completed tens of millions of yuan in B+ round financing, which was invested by Suzhou High-tech Venture Capital Group (hereinafter referred to as "Su Gaoxin Venture Capital").
”)
.
It is reported that this B+ round of financing will help the company to accelerate the upgrade of the AIBERT® (Oncology Multi-omics Data Mining System for New Drug Development) platform, including the computing module (bioinformatics platform) and the experimental module (multi-omics functional laboratory) ) construction
.
In addition, Nanjing Yuxi Pharmaceutical Technology Co.
, Ltd.
(hereinafter referred to as "Yuxi Medicine") also announced some time ago that it has completed the pre-A round of tens of millions of RMB financing
.
This round of financing was led by Materia Medica, followed by Jiuyou Capital, Chang Development, Aibo Qingshi and Mingfeng Capital
.
This round of financing will be mainly used for product clinical trials, pipeline research and development, innovative technology platform construction and team supplementation
.
In addition, Yuguo Bio also announced that it has completed a C round of financing of 300 million yuan, which was exclusively led by Shanghai Biomedical Fund, and the old shareholder LYFE Zhouling Capital joined the investment
.
According to the announcement, the raised funds will continue to be invested in the research and development of new products and the in-hospital localized deployment of pathogenic NGS
.
According to incomplete statistics, in January 2022, more than 20 pharmaceutical companies have completed investment in the field of new drugs, and the total financing amount has exceeded 5 billion yuan.
Among them, it is worth mentioning that industry analysts believe that from this year's financing of pharmaceutical companies.
In general, the focus of pharmaceutical companies is no longer the same as before, focusing on popular fields such as "tumor, car-t, double antibody", but gradually began to choose more unpopular and more subdivided field layouts
.
This means that segmentation and specialization may gradually become the only way for future innovative pharmaceutical companies
.
In this context, innovative pharmaceutical companies, focusing on subdivision fields, choose to become small and dedicated companies with characteristics, and in the future, it will be easier to obtain real core competitiveness.
It is recommended by the industry that related companies can deploy as soon as possible
.
